Cargando…

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide with a poor prognosis and high mortality. More than two-thirds of HNSCC patients still have no effective control of clinical progression, and the five-year survival rate is < 50%. Moreover, patients with p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Weimin, Chen, Miao, Hong, Le, Zhao, Hang, Chen, Qianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258806/
https://www.ncbi.nlm.nih.gov/pubmed/30519541
http://dx.doi.org/10.3389/fonc.2018.00532
_version_ 1783374562712354816
author Lin, Weimin
Chen, Miao
Hong, Le
Zhao, Hang
Chen, Qianming
author_facet Lin, Weimin
Chen, Miao
Hong, Le
Zhao, Hang
Chen, Qianming
author_sort Lin, Weimin
collection PubMed
description Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide with a poor prognosis and high mortality. More than two-thirds of HNSCC patients still have no effective control of clinical progression, and the five-year survival rate is < 50%. Moreover, patients with platinum-refractory HNSCC have a median survival of < 6 months. The significant toxicity and low survival rates of current treatment strategies highlight the necessity for new treatment modalities. Recently, a large number of studies have demonstrated that programmed cell death protein-1 (PD-1) and its ligand, programmed cell death protein ligand-1 (PD-L1) play an essential role in tumor initiation and progression. PD-1/PD-L1 blockade has shown a desired and long-lasting therapeutic effect in the treatment of HNSCC and other malignancies. However, only a small number of patients with HNSCC can benefit from PD-1/PD-L1 blockade monotherapy, while the majority of patients do not respond. To overcome the unsatisfactory therapeutic effect of PD-1/PD-L1 blockade monotherapy, combining other treatment options for HNSCC (including chemotherapy, radiotherapy, targeted therapy, and immunotherapy) in the treatment scheme has become a commonly used strategy. Herein, the potential mechanisms underlying the crosstalk between PD-1/PD-L1 blockade and its combinatorial therapies for HNSCC were reviewed, and it is hoped that the improved understanding of the crosstalk process would provide further ideas for the design of a combinatorial regimen with a higher efficiency and response rate for the treatment of HNSCC and other malignancies.
format Online
Article
Text
id pubmed-6258806
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62588062018-12-05 Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC Lin, Weimin Chen, Miao Hong, Le Zhao, Hang Chen, Qianming Front Oncol Oncology Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide with a poor prognosis and high mortality. More than two-thirds of HNSCC patients still have no effective control of clinical progression, and the five-year survival rate is < 50%. Moreover, patients with platinum-refractory HNSCC have a median survival of < 6 months. The significant toxicity and low survival rates of current treatment strategies highlight the necessity for new treatment modalities. Recently, a large number of studies have demonstrated that programmed cell death protein-1 (PD-1) and its ligand, programmed cell death protein ligand-1 (PD-L1) play an essential role in tumor initiation and progression. PD-1/PD-L1 blockade has shown a desired and long-lasting therapeutic effect in the treatment of HNSCC and other malignancies. However, only a small number of patients with HNSCC can benefit from PD-1/PD-L1 blockade monotherapy, while the majority of patients do not respond. To overcome the unsatisfactory therapeutic effect of PD-1/PD-L1 blockade monotherapy, combining other treatment options for HNSCC (including chemotherapy, radiotherapy, targeted therapy, and immunotherapy) in the treatment scheme has become a commonly used strategy. Herein, the potential mechanisms underlying the crosstalk between PD-1/PD-L1 blockade and its combinatorial therapies for HNSCC were reviewed, and it is hoped that the improved understanding of the crosstalk process would provide further ideas for the design of a combinatorial regimen with a higher efficiency and response rate for the treatment of HNSCC and other malignancies. Frontiers Media S.A. 2018-11-21 /pmc/articles/PMC6258806/ /pubmed/30519541 http://dx.doi.org/10.3389/fonc.2018.00532 Text en Copyright © 2018 Lin, Chen, Hong, Zhao and Chen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lin, Weimin
Chen, Miao
Hong, Le
Zhao, Hang
Chen, Qianming
Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
title Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
title_full Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
title_fullStr Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
title_full_unstemmed Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
title_short Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
title_sort crosstalk between pd-1/pd-l1 blockade and its combinatorial therapies in tumor immune microenvironment: a focus on hnscc
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258806/
https://www.ncbi.nlm.nih.gov/pubmed/30519541
http://dx.doi.org/10.3389/fonc.2018.00532
work_keys_str_mv AT linweimin crosstalkbetweenpd1pdl1blockadeanditscombinatorialtherapiesintumorimmunemicroenvironmentafocusonhnscc
AT chenmiao crosstalkbetweenpd1pdl1blockadeanditscombinatorialtherapiesintumorimmunemicroenvironmentafocusonhnscc
AT hongle crosstalkbetweenpd1pdl1blockadeanditscombinatorialtherapiesintumorimmunemicroenvironmentafocusonhnscc
AT zhaohang crosstalkbetweenpd1pdl1blockadeanditscombinatorialtherapiesintumorimmunemicroenvironmentafocusonhnscc
AT chenqianming crosstalkbetweenpd1pdl1blockadeanditscombinatorialtherapiesintumorimmunemicroenvironmentafocusonhnscc